While tumor mutational burden and PD-L1 expression remain standard markers, emerging biomarkers—such as circulating tumor DNA, gut microbiota composition, and immune gene signatures—are showing promise in predicting treatment response and adverse events [116,117]. This evidence concerns the gene CD274 and neoplasm.